Answers are grounded in this paper and cite their sources.
It is known that diabetes results from the inability of pancreatic islet cells to make insulin in amounts sufficient to control the blood glucose level. As efforts continue to identify an ultimate prevention or disease-modifying treatment (DMT) for diabetes, researchers have worked tirelessly to improve the lives of persons with diabetes, such as by developing more effective and user-friendly patient insulin monitoring and delivery devices. Public health researchers also have worked to lower the population risk of ever getting diabetes, and clinical researchers have identified secondary treatment strategies that mitigate problematic symptoms, improve function, and increase quality of life. So, as the search for a DMT continues, the diabetes research community has substantially improved the lives of persons who live with the condition. Finding a cure and improving treatment for persons who live with diabetes has occurred in tandem. Consider now Alzheimer’s disease and related dementias (ADRD), which have emerged as both a leading health-care and public health priority. With no known DMT, the increasing number of persons with ADRD and their caregivers has begun to stand apart among aging Americans, including those who live with diabetes and have been offered evidence-based treatments that address symptoms and improve quality of life. In comparison, persons with ADRD endure deterioration in cognitive abilities, passing through mild to severe clinical stages, that can last up to 20 years. During this long journey, more than one-half present affective, behavioral, and psychiatric disturbances, and many persons with ADRD are diagnosed with other health conditions and experience problems with nutrition, sleep, and chronic pain. Persons with ADRD use emergency rooms more than other older adults and they have greater numbers of ambulatory-sensitive inpatient hospital visits, overnight observations, and nursing home stays. Eventually, persons with ADRD may require full-time care, which is most often provided by a spouse, child, or other relative who has no formal training. Expensive and inefficient use of health care and long-term services and supports persists even though researchers have identified several pharmaceutical and nonpharmaceutical interventions proven to mitigate symptoms, delay unwanted residential placements, and reduce costs. There is a large and growing gap between what can be done to help and what is actually being done, and this gap only widens with the lack of public education, provider training, and implementation of proven care approaches (Kaskie & Stamy, 2018). Leaders of the Alzheimer’s movement certainly support policy-makers who look beyond supporting DMT discovery and also recognize the importance of expanding the dissemination and implementation of evidence-based treatments that address problematic symptoms and improve quality of life for persons with ADRD and their caregivers. As Jeff Cummings noted recently: A new study found methylphenidate to be effective in treating apathy in individuals with AD [Alzheimer’s disease]. At a time when the recent aducanumab approval is focusing attention on the promise of disease modifying therapies, the new findings highlight the importance of developing better symptomatic treatment options for individuals with psychiatric disorders of AD. (Cummings, 2022) Several pieces in this issue of the Public Policy and Aging Report highlight such contemporary efforts. Patricia Boyle and colleagues (2022) highlight the critical role that protective services offer to persons with ADRD who are at increased risk for financial fraud and other harms. Joe Gaugler (2022) reviews the National Family Caregiver Strategy, reporting how financing for evidence-based programs and services has increased over the past five years. Following on this, Catherine Riffin and colleagues (2022) highlight efforts to link informal caregivers with health-care providers as a proven way to improve ADRD care and reduce costs. Walt Dawson and Adelina Comas-Herrera (2022) consider how national planning efforts have been set back during the pandemic and discuss how critical it is for policy-makers to resume such efforts, given the negative outcomes experienced by persons with ADRD and their caregivers. Michael Gusmano (2022) reflects on how the recent approval of Aduhelm did not occur in isolation as much as coincide with scientific review process changes recently put in place by the Food and Drug Administration. Sarah Khasawinah (2022) recounts efforts to establish a federally supported public health infrastructure dedicated to ADRD (the Building Our Largest Dementia [BOLD] Infrastructure Act) and highlights the particular need to address social and behavioral determinants, such as social isolation, that impact persons with ADRD. Finally, Nora Super and Diane Ty (2022) affirm the role of advocacy and discuss how the Alliance to Improve Dementia Care works to coordinate efforts across multiple and varied organizations, including public agencies, nonprofits, and corporations that all have committed to advancing public policy on behalf of persons with ADRD and their caregivers. We are excited that federal allocations for the BOLD Act may surpass $25 million in 2022 and National Institutes of Health funding for the Imbedded Pragmatic AD/ADRD Clinical Trials (IMPACT) program may reach $50 million, and we also recognize that allocations for basic ADRD research will exceed $3.0 billion. So, as there is little disagreement among leaders of the Alzheimer’s movement, policy-makers must continue the vigorous expansion of the public infrastructure needed to educate and train care providers who can identify and refer persons who may be experiencing ADRD. Policy-makers also must continue to expand their support for the dissemination and implementation of evidence-based therapies. Similarly, although occupational and other therapeutic interventions have met the criteria of being evidence-based and Medicare now reimburses many of these services, the outlays appear minimal relative to what might be expected given the need for persons with ADRD to access evidence-based care. Several care management and caregiver support programs also have met research design standards of randomized clinical trials used for drugs and devices, yet their widespread implementation has been minimal. So, as we call on public policy-makers to invest even more into the public health infrastructure and increase provision of evidence-based treatments, we also call on health insurers and health system administrators to determine how value-based and other capitated payments are being allocated relative to what can be done to improve the lives of persons with ADRD and their caregivers. After all, treating symptoms is 90% of medicine, and doing so improves lives and saves money.
No takes yet. Share an insight, caveat, or question.
Kaskie et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: